InvestorsHub Logo
Followers 145
Posts 27561
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Wednesday, 12/29/2021 12:17:30 AM

Wednesday, December 29, 2021 12:17:30 AM

Post# of 190
FDA updates EUA for COVID convalescent plasma limiting use to certain patients

Dec. 28, 2021 5:28 PM ETADMA Biologics, Inc. KMDA

By: Jonathan Block, SA News Editor

The FDA has updated the Emergency Use Authorization ("EUA") for the use of convalescent plasma as a COVID-19 treatment for patients with immunosuppressive disease or receiving immunosuppressive treatment.

The FDA reiterated that the plasma product used must have high titers of anti-SARS-CoV-2 antibodies.

The FDA first issued the EUA in August 2020.

Convalescent plasma players: Kamada (NASDAQ:KMDA), Grifols (NASDAQ:GRFS), XBiotech (NASDAQ:XBIT), Cerus (NASDAQ:CERS), and ADMA Biologics (NASDAQ:ADMA).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KMDA News